MY PICK IS ELN

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Websman
    Senior Member
    • Apr 2004
    • 5545

    Statements show depth of bitterness in Geaney case

    PaulO'Kane
    FORMER Elan boss Donal Geaney was to have remained as chairman of the company when he resigned as chief executive in July 2002, he claims in legal documents prepared for his forthcoming court case against Elan.

    A series of witness statements, which have been seen by the Sunday Tribune, show that Geaney claims that, at a meeting in New York with three Elan directors, he was told that he had to resign as chief executive but could remain as chairman. Less than a week later, Geaney claims, he was informed that the board wanted him to relinquish both positions.

    "This came as a complete shock to me and I protested about the change in the previous position," Geaney claims. But he also claimed that, while he felt the procedures governing his removal had not been followed, it was not in the shareholders' interests for him to "engage in open warfare with Elan".

    The witness statements for the case, which relates to Geaney's alleged entitlement to exercise Elan share options worth $16.8m, show the depth of bitterness between the two sides. He claims he had two years in which to exercise the options after he left the payroll, but Elan disputes this.

    The case is due to begin tomorrow at the Commercial Court in Dublin and according to one well-placed source there are currently no settlement talks between the two sides. Elan will vigorously contest Geaney's version of events, claiming that he only had nine months in which to exercise his options.

    The witness statements also reveal that former Merrill Lynch boss Dan Tully, who was a director of Elan, was "upset, disappointed and indignant" at the manner in which certain members of the Elan board treated Geaney.
    Tully may appear as a witness for Geaney, while former deputy chief executive Tom Lynch is likely to appear as a witness for the company. Lynch, who resigned his executive role in Elan at the same time as Geaney, claims that it was his view that he would only have 90 days in which to exercise his options.

    The documents also reveal that, at the height of the crisis in 2002, Geaney became seriously ill and underwent major surgery. The Elan board considered announcing details of the illness but decided against it.

    Comment

    • Websman
      Senior Member
      • Apr 2004
      • 5545




      Elan Shares Gain After Study Reports on Tysabri Cases (Update3)
      June 10 (Bloomberg) -- Shares of Elan Corp. rose as much as 12 percent after a study suggested patients on its Tysabri medicine, withdrawn from the market because of a fatal nerve disorder, may be monitored early enough to prevent harm.

      Shares of the Irish drugmaker rose 37 cents, or 6.8 percent, to 5.80 euros at 11:30 a.m. in Dublin. Shares of its U.S. partner, Biogen Idec Inc., rose 5.3 percent to $35.13 yesterday after the New England Journal of Medicine released the report.

      The study found the virus that causes the nerve disorder was detected in a patient's blood samples months before that patient was hospitalized. The ability to monitor people taking Tysabri for the nerve disease, called progressive multifocal leukoencephalopathy, may enable doctors to detect PML early enough to prevent onset of the disease, according to Annette Langer-Gould, an MS specialist at Stanford University, who wrote one of the three studies.

      ``That the New England Journal of Medicine brought forward the publication of patient case detail is a reflection of the importance and impact of Tysabri in the MS and overall medical community,'' Jack Gorman, an analyst at Dublin-based Davy Stockbrokers said in a note today. The study ``offers some more insight on how Elan/Biogen is building a case for Tysabri's path forward,'' he said.

      The research is part of an analysis in the NEJM's July 28 issue of three cases of the Tysabri disorder that led to the drug's Feb. 28 withdrawal. The journal released the findings early after the U.S. Food and Drug Administration disclosed a possible fourth case of PML last week, NEJM editor-in-chief Jeffrey Drazen said yesterday in an interview.

      Shares of Elan have plunged 73 percent since Tysabri was pulled from the market, and Cambridge, Massachusetts-based Biogen shares have lost half their value since the withdrawal.

      ``It's relatively good news, but it's only an editorial,'' Mike Ward, an analyst at Code Securities in London said in an interview today. ``Extra work needs to be done before that is confirmed.''



      To contact the reporter on this story:
      Angela Zimm in London at at [email protected]

      Comment

      • kingofthehill
        Senior Member
        • Nov 2003
        • 487

        I am not worried at all about today EWall street journal story

        got this email from Ireland this AM

        "Elan Corporation: Unconfirmed reports of another PML case

        The Wall Street Journal reported this morning that another possible PML case has been detected in a patient on Tysabri in combination with four other drugs (including CellCept, an immunosuppressant for transplant patients). This case was apparently reported to the FDA on 16th May through the Adverse Event Reporting System and we would expect if positive that this would be confirmed case by now.

        Cellcept is an immunsuppressant approved for use in kidney, heart and liver transplants. It was previously indicated on the Tysabri label that patients receiving immunosuppressive agents should not receive concurrent therapy with Tysabri because of the possibility of increased risk of infections. Transplant patients are at increased risk of developing PML because of their immunocompromised state. In any future use of Tysabri, it is accepted that a combination of immunosuppressive drugs or immunomodulators (e.g. Avonex) will be avoided.

        If this patient highlighted in the WSJ is confirmed in combination with drugs that lead to immunosuppression, we continue to believe that Tysabri will return to the market as a monotherapy in multiple sclerosis. To date, two confirmed cases of PML have been in combination use and one case was reported when Tysabri was taken in combination with Azathioprine while been very immunosuppressed. A fourth possible case was highlighted almost two weeks ago which has not been confirmed. Given that this case report was submitted to the FDA in April 2005 we expect that if PMLdeveloped that this would be confirmed at this stage.

        Elan and BiogenIdec continue to methodically review the patients in the Tysabri clinical trials and we estimate the review will be completed over the coming weeks. Post completing the review Elan and BiogenIdec will meet the FDA with an FDA advisory meeting expected in late Q3/early Q4. As previously highlighted it is impossible to predict the outcome of the review and any advisory panel discussions, as further cases of PML may be uncovered although we would expect any confirmed cases of PML in patients to have been disclosed at this point.

        Orla Hartford
        NCB Stockbrokers
        +353 1 6115844"

        Comment

        • kingofthehill
          Senior Member
          • Nov 2003
          • 487

          Elan will be a $15.00 stock by NOVEMBER ! write it down ...KINGOF THE HILL



          Elan (Buy, Current Price $6.7
          Lack of response speaks volumes on suspected PML case.
          Yesterday, media reports indicated that a fifth suspected case of PML was reported through the FDA's Adverse Event Reporting System on 16 May. Potentially prescribed Tysabri rather than in clinical trails, the patient was apparently on dual therapy of Tysabri plus Avonex and was also on four other drugs including Cellcept. This drug is commonly given to transplant patients and carries a black box warning on its immunosuppressive side-effects, which can lead to increased susceptibility to infection and the possible development of lymphoma. Given (i) that the suspected case was reported a month ago; (ii) that no statement has been released by either Elan or Biogen Idec on the case; and (iii) the level of corporate activity and tenor of public statements by Elan over the past month while knowing of this case, we continue to believe from the information currently available that this, along with the fourth suspected case, is not deemed material to the progress of Tysabri through the review process. It is understandable that, after the withdrawal of Tysabri from the market, prescribing physicians will be extremely cautious. As such, they will be more likely to report any abnormalities in patients that were on Tysabri to the FDA. We believe, therefore, that there may be a number of such reports in the system that could come out under the disclosure of information act over the coming months. However, it is not the existence of such reports that is material, rather Elan and Biogen Idec's response. As such, under current regulatory conditions, we believe the market will be informed of material events, if any, in the Tysabri review by the companies well before it is "revealed" through freedom of information channels.

          Comment

          • lak
            Senior Member
            • Sep 2004
            • 124

            This is one a couple people I know are very tempted in.
            Reading this thread has become very interesting in the past couple of days.........
            Gotta love the big board!

            Comment

            • Websman
              Senior Member
              • Apr 2004
              • 5545

              I may get back in ELN tomorrow

              Comment

              • lak
                Senior Member
                • Sep 2004
                • 124

                Originally posted by Websman
                I may get back in ELN tomorrow
                Got that Vulcan feeling?
                Gotta love the big board!

                Comment

                • Websman
                  Senior Member
                  • Apr 2004
                  • 5545

                  Originally posted by lak
                  Got that Vulcan feeling?
                  I'll buy if it takes a dip...

                  Comment

                  • kingofthehill
                    Senior Member
                    • Nov 2003
                    • 487

                    ELN Elan chatter (7.19 +0.47)

                    ELN is breaking to a new session high on no news. We have heard two rumors today that could account for it: 1) takeover speculation, and 2) there could be a Tysabri announcement soon. We note that both rumors tend to make the rounds fairly frequently. Initial feedback we've heard is that a takeover is not likely, and we have no color on the Tysabri speculation.

                    Comment

                    • lak
                      Senior Member
                      • Sep 2004
                      • 124

                      Originally posted by kingofthehill
                      ELN Elan chatter (7.19 +0.47)

                      ELN is breaking to a new session high on no news. We have heard two rumors today that could account for it: 1) takeover speculation, and 2) there could be a Tysabri announcement soon. We note that both rumors tend to make the rounds fairly frequently. Initial feedback we've heard is that a takeover is not likely, and we have no color on the Tysabri speculation.
                      People seem to be paying attention to the rumors for sure. 7% move. Not bad for holders.
                      Gotta love the big board!

                      Comment

                      • kingofthehill
                        Senior Member
                        • Nov 2003
                        • 487

                        Tysabri news is my bet but maybe not today .. next 2 weeks for sure

                        Comment

                        • Websman
                          Senior Member
                          • Apr 2004
                          • 5545

                          Originally posted by kingofthehill
                          Tysabri news is my bet but maybe not today .. next 2 weeks for sure
                          I hope so, being I bought back in. Maybe I'll actually come out ahead this time.

                          Comment

                          • lak
                            Senior Member
                            • Sep 2004
                            • 124

                            I started a small position in ELN at 6.80 yesterday.
                            Perhaps we can all come out on top!
                            Gotta love the big board!

                            Comment

                            • kingofthehill
                              Senior Member
                              • Nov 2003
                              • 487

                              this is a copy of a post written by someone i know of and trust, its from the Elan message board on Yahoo.

                              FDA view of Tysabri ?
                              by: goodtoreadthis (59/M/Boston, MA) 06/15/05 07:22 pm
                              Msg: 692521 of 692536

                              Biotech analysts here in Boston have had, and continue to have, keen interest in the Tysabri situation. They are "pulsing" every avenue of information.

                              The following is an amalgum of what some of them think they have learned from Elan, BIIB, and Wash DC sources -possibly elements of FDA itself.

                              FDA is asking for a protocol for field test for JC virus in blood. FDA is DEMANDING that the field test be READY TO GO IN THIRD QUARTER 2005 AS PART OF THE RE-INTRODUCTION OF TYSABRI. PLEASE NOTE THIS IS AN FDA DEMAND.

                              The FDA is under such MONSTER POLITICAL PRESSURE TO RETURN TYSABRI TO MARKET that it is not requiring the field test be validated before re-launch of Tysabri.

                              Where is this political pressure coming from? As you know, about 4 weeks ago Mrs. Romney,an MS sufferer and wife of our Mass. governor expressed sincere regret that Tysabri, that had seemed such a beacon of hope for MSers, was taken off the market. As you know this MS scourge is considered more of a women's disease. Inquiring analysts are being told that the pressure is coming from the wives, mothers, sisters, daughters, and nieces of Congressman and US Senators who have MS, know people with MS, or have friends with MS.

                              As both BIIB and Elan have said, they have been constantly apprising the FDA on the investigatory details on Tysabri.

                              While BIIB senior managers are saying that they are blinded to the details, the FDA apparently is not.

                              The medical science community seems to be very favorably aligned to tysabri's return as indicated by the pre-publication release of data in the NEJM on the tysabri cases. That data indicated that tests could be run to deal with the risk of PML for MSers.

                              Patients, doctors, and their concerned friends appear to be speaking up forcefully for tysabri's quick return.

                              Comment

                              • Websman
                                Senior Member
                                • Apr 2004
                                • 5545

                                Originally posted by lak
                                I started a small position in ELN at 6.80 yesterday.
                                Perhaps we can all come out on top!
                                Our small positions could turn into huge positons overnight.

                                Comment

                                Working...
                                X